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IMPROVING RECRUITMENT TO PHARMACOLOGICAL TRIALS FOR ILLICIT 
OPIOID USE: FINDINGS FROM A QUALITATIVE FOCUS GROUP STUDY  
 
ABSTRACT 
 
Aim: To explore potential study participants’ views on willingness to join clinical trials of 
pharmacological interventions for illicit opioid use to inform and improve future recruitment 
strategies. 
Design: Qualitative focus group study (6 groups: oral methadone [2 groups]; buprenorphine 
tablets [2 groups]; injectable opioid agonist treatment [1 group]; and former opioid agonist 
treatment [1 group]). 
Settings: Drug and alcohol services and a peer support recovery service (London, United 
Kingdom). 
Participants: 40 people with experience of opioid agonist treatment for heroin dependence 
(26 males, 14 females; ages 33-66 years). 
Measurements: Data collection was facilitated by a topic guide that explored willingness to 
enrol in clinical pharmacological trials. Groups were audio-recorded and transcribed. 
Transcribed data were analysed inductively via Iterative Categorisation. 
Findings: Participants’ willingness to join pharmacological trials of medications for opioid 
dependence was affected by factors relating to study burden, study drug, study design, study 
population, and study relationships. Participants worried that the trial drug might be worse 
than, or interfere with, their current treatment. They also misunderstood aspects of trial 
design despite the researchers’ explanations.  
Conclusions: Recruitment of participants for clinical trials of pharmacological interventions 
for illicit opioid use could be improved if researchers became better at explaining clinical 
trials to potential participants, dispelling misconceptions about trials, and increasing trust in 
the research process and research establishment. A checklist of issues to consider when 
designing pharmacological trials for illicit opioid use is proposed. 
 
 
Key words: Qualitative study; clinical trials; pharmacological interventions; opioid 
dependence; study recruitment; opioid agonist treatment; ethics  
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IMPROVING RECRUITMENT TO PHARMACOLOGICAL TRIALS FOR ILLICIT 
OPIOID USE: FINDINGS FROM A QUALITATIVE INTERVIEW STUDY  
 
 
INTRODUCTION 
 
Pharmacological interventions play a critical role in the treatment of illicit opioid use. In 
1964, methadone was first tested as a long-term maintenance treatment in two patients 
previously maintained on morphine[1-3]. Methadone subsequently became the dominant 
medical treatment for opioid dependence[4], but the search for alternative and more effective 
medications has continued. Over the years, different drugs and drug combinations 
(naltrexone, buprenorphine, combined buprenorphine and naloxone, levo-alpha acetyl 
methadol, morphine, dihydrocodeine), as well as different dosing regimes (detoxification, 
reduction, maintenance) and formulations (liquids, tablets, implants, injectables), have 
emerged. In response to rapid global increases in opioid use and poor adherence to existing 
opioid medications[5], novel long-acting formulations (e.g. slow-release implants, depot 
injections) are also now being developed. 
 
Before new opioid medications receive regulatory approval, they need to be tested in clinical 
trials, including volunteer Phase 1 studies as well as randomized controlled trials (RCTs) with 
opioid-dependent patients, to demonstrate safety and efficacy[6]. Difficulties recruiting 
participants to RCTs are common within most medical research[7,8]; indeed, one review of 
RCTs across a range of medical conditions found that nearly half received an extension due 
to recruitment problems[9]. Many addiction trials have also reported problems achieving their 
target sample sizes or taking longer to recruit than planned[10-14]. According to one review, 
less than 45 out of every 100 potential participants in drug dependence RCTs were actually 
eligible, consented and did not drop out immediately after randomization[12].  
 
Researchers conducting trials of both pharmacological and psychosocial interventions for 
alcohol and other drug problems have sometimes published details of their recruitment 
difficulties. These data indicate that substance users can be deterred from participating in 
addiction trials because they do not like or cannot meet the conditions of treatment, such as 
having to attend appointments and services daily[11]; lack understanding of, or dislike, 
research[10,12]; have low motivation for treatment[10,14]; worry about their confidentiality, 
!
!
5 
privacy or lack of choice as trial participants[10]; are reluctant to be a ‘guinea pig’ or part of an 
‘experiment’[10]; and are concerned about being assigned to a placebo treatment[14,15] or 
control condition[10]. 
 
In addition, recruitment to alcohol and other drug trials can be hampered because clinic staff 
have insufficient interest, time or capacity to conduct the research[10,14,16,17]; forget or become 
confused by complicated entry criteria and so do not refer patients to the trial[14]; and do not 
understand or are sceptical about the research or the trial drug[10,17,18]. Other recruitment 
challenges are more practical, such as strict eligibility criteria that limit the pool of potential 
participants[10-13,19]; fewer potential participants than expected or needed in a particular area 
or service[10,13]; and difficulty contacting potential participants because they lack stable 
accommodation, move around, or change telephone numbers[13,20]. 
 
Responding to these problems, addiction researchers have already identified strategies that 
can be incorporated into their RCT designs to facilitate and enhance recruitment. These 
include offering financial reimbursements or incentives[14]; providing non-monetary 
incentives, such as coffee or bus tokens[21]; increasing the odds of receiving the experimental 
treatment[10]; simplifying the study referral processes[10,14]; providing treatments which appeal 
to the target population or are otherwise unavailable[13]; sending appointment reminders[10,14]; 
inviting trial participants to recruit others from their social networks[22]; highlighting the 
potential benefits of the study to patients and staff[14]; and engaging with peer and community 
organisations to secure their commitment to the research[13,21,22].  
 
Very few studies have, however, asked people who are dependent on drugs or alcohol for 
their views on clinical trial participation. A rare exception is a quantitative survey of 1,020 
illicit drug users recruited from community settings in Canada. This research identified high 
rates of willingness to participate in a pharmacological addiction treatment trial (58.3%), with 
those engaged in high-risk drug and sexual activities expressing greater willingness[23]. In 
addition, a qualitative study of 37 African American crack cocaine users already enrolled in 
three different behavioural HIV prevention studies found that decisions to participate in HIV-
related research (two behavioural interventions and a hepatitis vaccine project) were affected 
by the desire for information; scepticism and mistrust of research and researchers; 
perceptions of medical care and monitoring within the study; and participant control over 
decisions to enrol or not[24].  
!
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Lastly, a Belgian study of 52 heroin users who were eligible for, but not recruited to, a 
heroin-assisted treatment trial concluded that non-enrolment related to the trial conditions and 
fear of becoming more dependent because of the trial treatment[11]. The data were, however, 
quantitative, descriptive and related to one specific heroin-assisted treatment trial. Qualitative 
research is particularly suited to providing detailed insights into how and why people who use 
substances think and act as they do and has often been used, in related areas, to investigate 
drug treatment and its effectiveness[25]. Despite this, we are aware of no qualitative studies of 
recruitment to clinical trials of pharmacological interventions for illicit opioid use. The aim of 
our study was to explore potential study participants’ views on willingness to join such trials 
in order to inform and improve future recruitment strategies. 
 
 
METHODS 
 
Data were collected via six focus groups (FGs) conducted with 40 people who were currently 
being treated, or who had previously been treated, with opioid agonist treatment (OAT) for 
heroin dependence (26 males, 14 females; ages 33-66 years). Groups were deliberately 
stratified by treatment drug and treatment status to prevent participants comparing their own 
treatment with other treatments and then becoming dissatisfied. The groups were: oral 
methadone (2 groups); buprenorphine tablets (2 groups); injectable OAT (1 group); and 
former OAT (1 group). Each group comprised 4-8 participants (see Table 1 for additional 
participant details). The study received ethical approval from the United Kingdom (UK) NHS 
Research Ethics Service. 
 
TABLE 1 
 
The groups were conducted in drug and alcohol services and a peer support recovery service 
in London, UK, during March and April 2017. To optimise recruitment, posters with the 
researchers’ contact details were displayed in the services; researchers approached potential 
participants in person at the services; workers encouraged service users to contact the 
researchers; and participants from the earlier focus groups introduced the research to their 
peers (‘snowball sampling’). Everyone who expressed interest in taking part (n=75) answered 
a simple screening questionnaire that covered gender, age, ethnicity, substance use, 
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prescribed medications, and contact details. The researchers then used the screening 
information to identify and invite up to 10 people (both sexes and different ethnic 
backgrounds but with the same current medication) to each group.  
 
Data collection was facilitated by two researchers who used a topic guide to gently steer the 
discussions whilst also allowing participants to raise issues spontaneously. The guide focused 
on participants’ willingness to join clinical trials of pharmacological interventions for illicit 
opioid dependence, including factors that might encourage or discourage participation. The 
researchers gave verbal explanations of trial methodology and presented three example study 
designs to increase participants’ understanding and encourage discussion around technical 
issues, such as randomization, blinding, and placebo treatment. The researchers also 
answered participants’ questions. Groups were audio-recorded and participants were offered 
refreshments and £10 as a gesture of thanks. 
 
The audio recordings lasted 44-64 minutes and were transcribed verbatim by a professional 
transcriber. All transcribed data were then analysed inductively through a process of Iterative 
Categorisation[26]. No specialist coding software or deductive codes were used. First, each 
focus group was analysed in isolation within Microsoft Word. To this end, each transcription 
was reviewed line by line by the lead author to identify recurrent themes in the data. These 
themes were then grouped into categories, discussed within the team, and summarised in a 
new Word document. This process enabled us to a) capture the nature of the discussion 
within each group, including the extent to which participants agreed or disagreed with each 
other and b) assess whether the themes and categories identified were similar across the 
groups.  
 
In practice, there were some differences of opinion between participants within individual 
groups but no notable differences of opinion when findings were compared across the groups. 
For example, within groups participants debated and often failed to agree on whether or not 
opioid users would participate in a trial without financial compensation. However, this same 
debate and lack of agreement was replicated across groups. Meanwhile, the themes and 
categories identified within each group were very similar, but not exactly the same across 
groups (an unsurprising outcome given that the focus group facilitators had used the topic 
guide flexibly and encouraged free discussion within each group). In order to capture the full 
spectrum of responses, we therefore merged the themes from each of the six groups into a 
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further Word document and then re-reviewed, re-ordered and re-categorised the themes 
inductively. By the end of this process, all identified themes had been categorised under one 
of five headings: 1. Study burden; 2. Study drug; 3. Study design; 4. Study population; and 5. 
Study relationships. Findings are presented descriptively and then reviewed more critically in 
the Discussion. 
 
 
FINDINGS  
 
1. Study burden 
 
Participants reported that their willingness to join a clinical trial of an opioid medication 
would be undermined if involvement created too many demands for them (see Table 2). In 
particular, they felt that the financial costs of travel to and from a trial site, as well as the 
physical difficulty of travelling with pre-existing health and mobility problems, were 
important barriers to participation. Some emphasized that travel could leave them feeling 
exhausted, so limiting their ability to undertake other activities for the rest of the day. Others 
complained that trials requiring daily travel to a study site, or the completion of multiple tasks 
each time they attended a study site, were especially demanding.  
 
Generally, participants believed that current and former heroin users would be reluctant to 
join trials if they had to provide blood samples since poor venous access could make this 
difficult. Moreover, needles could trigger a desire to inject. In addition, some expressed 
concerns that urine drug screening was intrusive and positive test results could have negative 
consequences for them (e.g. existing treatment might be altered, reduced or stopped). 
Participants also tended to report that studies lasting longer than one month were less 
acceptable since they locked people into treatment, limited treatment flexibility and choice, 
and potentially interfered with people’s own treatment goals by, for example, precluding the 
option of abstinence. 
 
Despite these concerns, participants suggested various ways that the burden of trial 
participation might be reduced. For example, many indicated that they would be more likely 
to enrol in a trial if the study site was near to where they lived, as this reduced their travel and 
associated costs. Some also suggested that study medications could be brought to their homes 
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or dispensed via a mobile treatment van. Most participants felt that researchers should 
provide travel passes or a taxi to take them to the study site and, at the very least, reimburse 
all travel costs. Offering flexibility in terms of when people could attend for treatment and 
posting any questionnaires to them for home completion were also proposed as ways of 
making participation less arduous. Finally, participants frequently argued that trials should be 
as short as possible (ideally less than a month).  
 
 
TABLE 2 
 
 
2. Study drug  
 
Anxieties about the pharmacology of the study drug, with particular concerns that it might 
cause withdrawal symptoms, also seemed to discourage trial participation (see Table 3). 
Withdrawal symptoms were almost universally feared on the grounds that they were 
distressing, could prompt former heroin users to relapse, and might expose pain that had 
previously been masked by opioids. Some participants argued that they would be reluctant to 
join pharmacological trials because they would be afraid of how a study drug might interact 
with any other medications they were taking or because of previous bad experiences after 
taking street or prescribed drugs. Indeed, some said that they would not personally participate 
in a trial under any circumstances if they did not like, or had heard bad things about, the trial 
drug. Meanwhile, nearly all emphasized that they would not join first-in-human trials because 
of the lack of evidence on the medication and its side effects. 
 
Participants nonetheless volunteered strategies that researchers could deploy to mitigate their 
anxieties. For example, some explained that they would be more willing to participate in a 
trial, even if withdrawal symptoms might occur, if they were reassured that they would have 
access to their own ‘regular’ opioid medications; offered a special supply of ‘rescue opioids’; 
given some control over the study dose; or promised direct and immediate access to medical 
care. Participants also often stated that having clear information about the trial drug might 
allay concerns. Specifically, they wanted to know the chemical structure of the trial drug, 
potential side effects, and how it had performed in any animal or first-in-human studies. 
Participants additionally reported greater willingness to enrol in a trial if they had written 
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agreement, a formal ‘contract’, or a note on their medical records that confirmed they could 
leave the trial and return to their previous medication at any time.  
 
 
TABLE 3 
 
 
3. Study design 
 
Aspects of the study design were also identified as barriers to recruitment (see Table 4). 
Participants occasionally reported that they would not enrol in a trial if the aim was unclear or 
if they thought that the study would not recruit. Others stated that they would be reluctant to 
participate if they believed that those recruited would be able to supplement the trial 
medication with illicit drugs, so compromising the study results. Participants also frequently 
questioned the feasibility of giving opioid users placebo drugs or blinding them to treatment 
given that people who are dependent on opioids know the effects and side effects of opioid 
medications and would recognise if they were receiving a different drug.  
 
Overall, participants were negative about randomization and blinding, arguing that they 
disliked not knowing what medication they would be receiving, the lack of choice, and not 
feeling in control. Crucially, not knowing one’s medication meant that they could not assess 
the likelihood that they would experience withdrawal symptoms or other adverse reactions, 
their ability to receive pain relief in the event of an accident, or how they would feel more 
generally. Other participants reported that they would not enrol in a trial if there was 
uncertainty about the length of time it would take to return to their pre-trial medication once 
the study ended or if the trial required them to attend services where staff had previously 
exhibited negative or stigmatizing attitudes towards them. 
 
Yet again, however, participants provided suggestions on how trials might be improved to 
increase recruitment. Most reported that current and former heroin users would be more 
willing to join a trial if the rationale for, and processes of, blinding and randomization were 
clearly explained. Some also stated that they would be more prepared to participate in studies 
(particularly those likely to induce withdrawal symptoms) if they took place in a safe, 
comfortable, controlled environment, such as a hospital, where there were activities (e.g. play 
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stations and television), nurses or medical staff, round-the-clock monitoring, and alternative 
medications if the treatment drug did not work. Lastly, one participant reported that she 
would be more likely to join a trial if she had reassurance that she would still be able to see 
her keyworker as usual. 
 
 
TABLE 4 
 
 
4. Study population 
 
Participants emphasized that readiness to join a clinical drug trial would invariably be 
influenced by an individual’s treatment status prior to study enrolment (see Table 5). For 
example, most agreed that former heroin users who were happy with their current treatment 
would be less likely to enrol in a medication trial as they would not want to jeopardize a 
treatment that was already working for them, particularly if they had struggled to secure the 
treatment and were now stable and not using illicit drugs. In contrast, participants generally 
felt that opioid users would be more likely to participate in a trial if they were dissatisfied 
with their current treatment, thought that the trial treatment might be preferable to their 
current treatment, or were desperate for treatment. 
 
 
TABLE 5 
 
 
5. Study relationships 
 
Lastly, participants reported that lack of trust in people, systems and organisations associated 
with drug trials would discourage study enrolment (see Table 6). In particular, they 
emphasized their distrust of the pharmaceutical industry, noting how pharmaceutical 
companies make mistakes when conducting research and yet still generate ‘huge’ profits. 
Some participants also highlighted their mistrust of doctors and the addiction treatment 
system, adding that service providers are constantly changing, the treatment system is 
unstable, and they would be reluctant trust anyone who promised them that their medication 
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would be re-instated if they left a trial. Beyond this, there was a general concern that their 
personal details might be passed on to others not involved in the research. 
 
Participants nonetheless identified ways that relationships with those conducting trials might 
be improved. For example, some reported that involving current and former heroin users in 
the design of a study would increase willingness to participate as it demonstrated that 
researchers were receptive to their views. Participants also felt that they might be encouraged 
to join a study after listening to peers or clinicians who were enthusiastic about the trial. 
Above all else, however, participants stressed the importance of cash incentives, explaining 
that these put them into a more formal contractual relationship with researchers but also 
showed that researchers valued their input. Indeed, some thought that cash payments were 
essential given that trials could not occur without current or former heroin users, that 
participant reimbursement for opioid dependence trials should match reimbursement for other 
industry-sponsored trials, and that the payment level should depend on the risks and 
discomfort likely to be experienced.  
 
Although cash incentives were nearly always preferred, some participants still felt that non-
cash payments (e.g. store vouchers, transport passes, food vouchers or gym memberships) 
were effective forms of incentivisation and recognition, especially if study participants could 
choose the type of non-cash payment received. In addition, some suggested that promising 
current heroin users a fast track into treatment, or a place in residential treatment, on 
completion of the trial might increase recruitment. Lastly, a small number of participants 
stated that they would be prepared to join a trial without any compensation at all in order to 
help others; specifically, they wanted to contribute to research, facilitate better future 
treatment options, and help save lives. 
 
 
TABLE 6 
 
 
DISCUSSION 
 
We conducted a small qualitative study that focused on recruitment to trials of 
pharmacological interventions for illicit opioid dependence. Data collection was narrow in 
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scope and only involved people who had received OAT for heroin use. The analyses 
undertaken were exploratory and caution should therefore be taken in generalizing from the 
findings. Despite this, themes identified supported international research on factors that 
hinder and facilitate recruitment to trials of both pharmacological and psychosocial addiction 
interventions. For example, participants reported that study enrolment was deterred by the 
burden and conditions of involvement[11,20]; concerns about confidentiality[10]; mistrust of 
researchers[24]; and reluctance to be a treatment ‘guinea pig’[10]. In contrast, recruitment was 
encouraged by access to study information[24]; the presence of medical care and 
monitoring[24]; treatments being desirable[13]; and reimbursements or incentives[14,21]. 
 
Findings were not, however, entirely consistent with previous research. Participants did not 
express concerns about the placebo or control condition[10,14,15]; instead they were more 
anxious about the treatment drug. They also did not seem to be worried by limited trial 
duration[11]; on the contrary, they recommended that trials should be as short as possible. 
Other issues that concerned the participants have not been well-documented previously, 
including the side effects of the study drug (especially withdrawal symptoms and interactions 
with other medications); perceived weaknesses in the trial design (uncertainty about the aim, 
feasibility, randomization, blinding, setting, and post-trial procedures); already being satisfied 
with, or making good progress on, a current medication; and lack of trust in the 
pharmaceutical industry and treatment system. In short, participants worried that the trial 
drug might be worse than their current treatment; a reminder that people already receiving 
medication for heroin dependence will likely have different concerns about trial participation 
than those not currently in treatment. 
 
Crucially, participants also made some observations about clinical trials that seemed to be 
confused or misinformed. For example, many expressed concerns about having to take drugs 
with unknown effects, being trapped in trials without being able to leave, having a pre-
existing valued treatment disrupted, and not knowing what would happen to them once the 
trial finished. In practice, of course, trial protocols are carefully reviewed by funders and 
ethics committees and subsequently scrutinized by trial steering committees. Furthermore, all 
patients are given detailed information about the trial procedures and medication, and patient 
safety and confidentiality are paramount. Nevertheless, the concerns expressed by our 
participants were substantial. They additionally suggested that recruitment could be improved 
by restricting studies to less than a month in duration, allowing them to have control over the 
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study drug, ensuring that they knew exactly what drug they were taking, and targeting 
recruitment at people who were dissatisfied with their current treatment or desperate for 
treatment. Trial protocols are, however, bound by strict methodological criteria and 
processes, including eligibility, randomization and blinding. Consequently, researchers 
cannot necessarily change study designs in the ways that participants suggested.  
 
Misconceptions and misunderstandings about clinical trials occurred in our study, even 
though the focus group facilitators talked participants through example trials and answered 
any participant questions. Poor research literacy has been reported in other addiction 
pharmacological trials and is known to hinder trial recruitment[10,24,27]. For example, one 
Australian survey revealed that many trial naïve injecting drug users did not understand key 
clinical trial concepts, such as blinding, placebo, equipoise and randomization, even after 
detailed verbal explanations. Meanwhile injecting drug users who demonstrated an 
understanding of placebo and double blinding were significantly more likely to perceive 
those concepts as acceptable compared with those who did not[28].  
 
Ensuring that trial participants fully understand what will happen to them is an ethical 
requirement, especially vital given that financial incentives could attract otherwise reluctant 
people into pharmacological research. Participant understanding is clearly hindered by the 
complexity of trial designs and technical terminology. However, lack of trust in those 
associated with the research process (in this study, the pharmaceutical industry and treatment 
providers) will likely compound misunderstanding as well as deter engagement. This is a 
difficult problem to overcome but not insurmountable. Trial information does not have to be 
provided only via dense documents and formal information sheets delivered by researchers or 
clinicians. It can also be made available via informal media (such as video or social media) 
using accessible language and images which potential participants can view at the recruitment 
sites and elsewhere; enhanced consent forms or extended discussion during the consenting 
process[29]; or interactive events hosted jointly with opioid users (including those who have 
already participated in similar trials) as part of a collaborative research effort[30].  
 
To help improve future recruitment strategies we have used our findings to develop a 
checklist that researchers may wish to consider when designing new pharmacological trials 
for illicit opioid dependence (see Table 7). The checklist comprises 32 issues relating to the 
five domains identified in the focus groups: study burden; study drug; study design; study 
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population; and study relationships. We do not suggest that these are the only issues that 
researchers should consider and we recognise that some issues will be more relevant to some 
trials than others. We also note that the checklist is likely to require revision following further 
research. Nonetheless, it should offer a useful and immediate starting point. 
 
TABLE 7 
 
 
 
CONCLUSIONS 
 
Recruiting to clinical trials of medications for illicit opioid use is a complex practical and 
ethical process. There are many pitfalls and barriers and whether or not any particular 
individual will enrol will depend on a multiplicity of factors. Although many early clinical 
trials (Phase 0-II) do not require large numbers of participants to be viable, RCTs need bigger 
sample sizes, are expensive if they over-run, and delay advances in treatment if they fail. 
Poor trial recruitment can also produce unrepresentative samples that undermine study 
results[12].  
 
Despite the various difficulties identified, the overall message from our research is positive. 
Firstly, participants in all six focus groups proactively identified strategies to encourage and 
facilitate trial recruitment, so demonstrating a basic desire to improve clinical 
pharmacological research. Secondly, some participants expressed a strong personal desire to 
participate in clinical trials without reimbursement or incentivisation, just because they 
wanted to help others. Thirdly, many reported that they could be encouraged to participate if 
the conditions and circumstances for involvement felt right. And fourthly, many more might 
be willing to participate if we become better at explaining trials to them, dispelling 
misconceptions, and increasing trust in the research process and the research establishment.  
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Table 1: Participant details  
Demographic characteristics FG a 1 
Oral 
methadone 
(n=4)  
FG2  
Oral 
methadone 
(n=8) 
FG3  
Buprenorphine 
tablets 
(n=8) 
FG4 
Buprenorphine 
tablets 
(n=8) 
FG5 
Injectable 
OATb 
 (n=6) 
FG6 
Former OAT 
 
(n=6) 
All 
(n=40) 
Gender        
Male 2 (50%) 5 (63%) 6 (75%) 5 (63%) 4 (67%) 4 (67%) 26 (65%) 
Female 2 (50%) 3 (38%) 2 (25%) 3 (38%) 2 (33%) 2 (33%) 14 (35%) 
        
Ethnicity        
White /White Britishc 2 4 6 6 5 4 27 (68%) 
Asian /Asian British 0 0 0 0 0 0 0 (0%) 
Black /Black British 2 2 1 0 0 2 7 (18%) 
Mixed or Multiple 0 1 1 1 0 0 3 (8%) 
Other 0 1 0 1 1 0 3 (8%) 
        
Age        
Mean age (years) 
(range) 
49  
(42-59) 
51  
(43-58) 
46  
(33-55) 
40 
(34-47) 
56 
(47-66) 
47  
(39-58) 
48 
(33-66) 
        
Street opioid use        
Mean age of first use 
(range) 
23 
(16-33) 
18 
(14-22) 
24 
(14-31) 
23 
(14-35) 
18 
(15-27) 
22 
(15-32) 
21 
(14-35) 
Mean duration of use  
(range)  
26 
(22-30) 
33 
(25-39) 
22 
(2-37) 
17 
(0-33) 
39 
(27-50) 
n/a 27 
(0-50) 
Current street opioid use  4 (100%) 6 (75%) 4 (50%) 2 (25%) 2 (33%) n/a 18 (53%) 
        
Current treatmentd        
None 0 0 0 0 0 6 6 (15%) 
Buprenorphine (tablets) 0 0 8 8 0 0 16 (40%) 
Methadone (oral) 4 8 0 0 2 0 14 (35%) 
Methadone (injection) 0 0 0 0 2 0 2 (5%) 
Diamorphine (injection) 0 0 0 0 4 0 4 (10%) 
a Focus group; b Opioid agonist treatment; c 19 participants identified as ‘British’, 4 as ‘Italian’, 3 as ‘Irish’, and 1 as ‘European’; d 2 participants were prescribed a 
combination of opioid medications (injectable + oral). The denominator used for the calculation of percentages across all subjects was n=40. Because two subjects from FG5 
were included in the percentages for ‘Current treatment’ twice, the total percentage across all 40 subjects adds up to 105%.  
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Table 2: Study burden  
 
THEME EXAMPLE QUOTATION 
Discouraging participation 
i. Travel 
ii. Daily attendance requirements 
iii. Numerous study components 
iv. Toxicology testing 
v. Study length > 1 month 
“Going to the chemist every day is a bind... It ties you to the 
chemist, you can’t go away.” (Female, FG2) 
 
“You’ve got to come every week to have a drug test, which 
is a bit intrusive.” (Male, FG3) 
Encouraging participation 
i. Local study sites 
ii. Free transport 
iii. Attendance flexibility 
iv. Minimal tasks per treatment site visit 
v. Minimal study duration 
“Send a cab around… to pick you up and take you there.” 
(Male, FG3) 
 
“Shorter trials are more acceptable to our community.” 
(Female, FG5) 
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Table 3: Study drug 
 
THEME EXAMPLE QUOTATION 
Discouraging participation 
i. Potential for withdrawal symptoms 
ii. Interactions with regular medication 
iii. Previous adverse drug reaction 
iv. Dislike of the treatment drug 
v. First-in-human studies 
“I’ve had bad, bad experiences with buprenorphine and 
Subutex. Because of that experience… I’d be scared to take a 
new trial drug now.” (Female, FG6) 
 
“I don’t think people like the idea of… [being] a guinea pig.” 
(Male FG1) 
Encouraging participation 
i. Availability of ‘rescue opioids’ 
ii. Control over study dose 
iii. Direct access to medical care  
iv. Good information about trial drug 
v. Contract or ‘opt out’ clause 
“There’d need to be… some kind of safeguard possibly, 
whether that be methadone or a morphine amp [ampoule] or 
something.” (Male, FG2) 
 
“I would want it written down, definitely, in black and white, 
that if I didn’t get on with it [trial medication], for whatever 
reason… I can go back to my previous prescription.” 
(Female, FG3) 
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Table 4: Study design 
 
THEME EXAMPLE QUOTATION 
Discouraging participation 
i. Unclear study aim 
ii. Uncertain study feasibility 
iii. Randomization & blinding 
iv. Uncertainty over post-trial medication 
v. Unsuitable study site 
“Unless you incarcerate me or hold me in a controlled 
environment, I’m going to abuse your test. I’m going to go 
and use other drugs, so it’s going to affect it [the trial].” 
(Male, FG4)  
 
“Blinding wouldn’t work as people would be able to tell 
what medication they were getting from bodily functioning 
and how they are feeling.” (Female, FG2) 
Encouraging participation 
i. Good study information 
ii. Controlled study environment 
iii. Reassurance about wrap-around support 
“I need to know about this medication. I need to have more 
information. About everything. About side effects, about 
everything.” (Male, FG1) 
 
“As long as there’s overseers and like doctors around, I 
wouldn’t mind trying it.” (Female, FG1) 
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Table 5: Study population 
 
THEME EXAMPLE QUOTATION 
Discouraging participation 
i. People satisfied with current treatment “People that are stable, they’ve stabilised their dose already, 
they’re not going to mess with it [current prescription].” 
(Male, FG5) 
 
“The risk of losing your existing drug, or even reducing, 
outweighs any financial [incentive].” (Male, FG4) 
Encouraging participation 
i. People dissatisfied with current treatment 
ii. People desperate for treatment 
“I’d be always willing to try a new medication if it’s 
different from methadone.” (Male, FG1) 
 
“People that are struggling to get into rehabs… You’re in 
trouble, you’re on death’s door, you’ve scratched the bottom 
of the barrel, you need help. You’re probably going to go for 
things like this.” (Male, FG4) 
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Table 6: Study relationships 
 
THEME EXAMPLE QUOTATION 
Discouraging participation 
i. Lack of trust in the pharmaceutical 
industry 
ii. Lack of trust in the treatment system 
iii. Concerns about the confidentiality of 
personal data 
“It’s about trust. Do I trust the medical industry?... At the 
end of the day they do make a lot of mistakes.” (Male, FG4) 
 
“I don’t want to be getting letters from every other drug 
company in the country.” (Male, FG3) 
Encouraging participation 
i. Service user involvement 
ii. Persuasion from a trusted other 
iii. Cash payments 
iv. Non-cash payments 
v. Altruism 
“I have to be compensated for my time, so money.” (Female, 
FG1)  
 
“I’d do it to help others further down the line.” (Male, FG3)   
 
 
 
  
!
!
26 
Table 7: Checklist to increase potential participants’ willingness to enrol in clinical 
trials of pharmacological interventions for illicit opioid use - Version 1 
 
A. Study burden 
1. Minimise travel to the study site (distance and costs) 
2. Provide transport to the travel site if possible 
3. Consider home delivery of treatment medications or delivery by mobile treatment van 
4. Consider home completion of questionnaires or routine data collection/ trial monitoring 
5. Reimburse any travel costs 
6. Be flexible whenever possible in relation to attendance requirements at the study site 
7. Minimise the number of study tasks per visit to the study site 
8. Avoid unnecessary toxicology screening 
9. Keep the study duration as short as possible 
B. Study drug 
10. Provide clear, comprehensive and accessible information on the trial drug (including any research 
evidence, particularly the potential for withdrawal symptoms and side effects) 
11. Discuss potential drug/ medication interactions on an individual basis 
12. Provide information on the availability of ‘rescue opioids’ if needed 
13. Provide information on the availability of other medical care if needed 
14. Offer participants a written contract or formal note on their medical records regarding ‘opting out’ or 
leaving the study and returning to their previous treatment 
C. Study design 
15. Explain the study aims, methods, and recruitment strategy using a range of accessible media (in 
addition to any formal written study documentation) 
16. Provide a clear explanation of the reasons for blinding and randomization 
17. Provide clear information on what will happen at the end of the trial or if the participant leaves the trial 
18. Ensure the study site is comfortable and welcoming, and that potential participants are not likely to feel 
uncomfortable or stigmatized 
19. Ensure that participants have access to recreational activities during time spent at the study site (e.g. 
television, reading materials, computers, game consoles) 
20. Ensure that medical professionals and the availability of medical care are visible at study sites  
21. Provide participants with information about how the trial will or will not affect any other support or 
services they receive 
D. Study population 
22. Consider both scientific and ethical factors before targeting vulnerable or treatment dissatisfied sub-
groups of opioid users who might be more desperate for treatment and therefore more willing to 
participate 
E. Study relationships 
23. Consider the potentially negative impact on recruitment if the study is funded by the pharmaceutical 
industry or the treatment system is perceived as unstable 
24. Work collaboratively with current and former illicit opioid users in designing the trial (patient and 
public involvement is often a requirement of health funding bodies) 
25. Invite enthusiastic clinicians and illicit opioid users who have ever previously participated in research 
to talk about the study at events or via social media 
26. Invite enthusiastic clinicians and opioid users who have ever previously participated in research to help 
recruit to the study 
27. Offer financial payments that are respectful of the demands of participation and the level of risk 
involved 
28. If non-cash payments are offered, allow participants some choice regarding the type of voucher or 
incentive 
29. Consider whether, and if so how, payments (financial or non-cash) might bias the sample 
30. Provide reassurances about the confidentiality of the data 
31. Remember (and respect the fact) that some opioid users will participate in pharmacological trials for 
altruistic reasons  
32. Express thanks when opioid users agree to participate 
 
 
 
 
